JAAOS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Am Acad Orthop Surg, Vol 12, No 1, January/February 2004, 55-64.
© 2004 the American Academy of Orthopaedic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siegel, H. J.
Right arrow Articles by Siegel, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siegel, H. J.
Right arrow Articles by Siegel, M. E.

Advances in Radionuclide Therapeutics in Orthopaedics

Herrick J. Siegel, MD, James V. Luck, Jr, MD and Michael E. Siegel, MD

Dr. H. Siegel is Assistant Professor, Division of Orthopaedic Surgery, Section of Orthopaedic Oncology, University of Alabama at Birmingham, Birmingham, AL. Dr. Luck is Professor, Department of Orthopaedic Surgery, UCLA/Orthopaedic Hospital of Los Angeles, Los Angeles, CA. Dr. M. Siegel is Professor of Radiology, Department of Nuclear Medicine, Orthopaedic Hospital of Los Angeles and Division of Nuclear Medicine, Los Angeles County + University of Southern California Medical Center, Los Angeles.

Reprint requests: Dr. H. Siegel, University of Alabama, Medical Faculty Office Towers #920, 510 20th Street South, Birmingham, AL 35294.

Radiopharmaceuticals not only are used for diagnostic purposes but also increasingly in the treatment of many orthopaedic-related disorders. With the development of specific bone-seeking radiopharmaceuticals, the side effects of treatment are minimized, therapeutic effects are sustained, and concomitant use with other modalities may have synergistic effects. These new radiopharmaceuticals, such as strontium 89 and samarium 153-ethylene diamine tetramethylene phosphate, have been used as palliative treatment for patients with bone pain from osseous metastases. Excellent clinical responses with acceptable hematologic toxicity have been observed, and clinical results rival those of external beam radiation therapy. Radiosynovectomy has become a procedure of choice at many institutions to treat recurrent hemarthrosis and chronic synovitis in patients whose hemophilia is poorly controlled with medical management. Radiosynovectomy also remains a viable option to treat chronic synovitis secondary to inflammatory arthropathies, particularly rheumatoid arthritis.




This article has been cited by other articles:


Home page
 JNMHome page
P. Schneider, J. Farahati, and C. Reiners
Radiosynovectomy in Rheumatology, Orthopedics, and Hemophilia
J. Nucl. Med., January 1, 2005; 46(1_suppl): 48S - 54S.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Academy of Orthopaedic Surgeons.